Osteoporosis in patients with polymyositis and/or dermatomyositis
Authors:
K. Pavelka; T. Zitko; R. Svobodová; L. Forejtová
Authors‘ workplace:
Revmatologický ústav, Praha
Published in:
Čes. Revmatol., 13, 2005, No. 1, p. 8-13.
Category:
Original Papers
Overview
The authors examined 45 patients with polymyositis or dermatomyositis (PM/DM) in cross-sectional, retrospective study. The disease was active in all the patients who were treated with a mean daily dose of 21.8 mg 5 ± 19.1 of prednisone or its equivalent. The mean duration of the disease was 5 years and 4 months. Twenty-one from 45 patients (46,7 %) had vertebral fractures verified by X-ray. Mean age of patients was 51.5 ± 13.8 years. Evaluation of bone mineral density revealed osteoporosis in 22% and osteopenia in 34% patients. It was observed that patients with fractures were older and duration of the disease was longer when PM/DM groups with and without fractures were compared. The relation between corticosteroid daily and cumulative dose and fracture occurrence was not found. There was no significant difference in biochemical markers in groups with and without fractures as well. The authors conclude that glucocorticoid-induced osteoporosis is a serious issue which in PM/DM has probably multifactorial causes. Treatment with bisphosphonates is recommended already when BMD decreased to -1.5 SD.
Key words:
glucocorticoid-induced OP, polymyositis, dermatomyositis
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2005 Issue 1
Most read in this issue
- Potential therapeutic approaches in polymyositis and dermatomyositis
- Chlamydia trachomatis and Chlamydophilla pneumoniae antibodies in a cohort of rheumatic patients
- Combined involvement of CNS and pituitary gland as a primary manifestation of Wegener’s granulomatosis
- Relevance of anti-nucleosome antibodies detected by enzyme – based immunoassays in lupus diagnosis. Comparative analysis of three commercial kits